An Expert Report on Ivabradine (DB09083)

Executive Summary

[Ivabradine is a first-in-class cardiovascular therapeutic agent that functions as a selective and specific inhibitor of the cardiac pacemaker current, designated as If​.][1][ This unique mechanism of action establishes it as a "pure" heart-rate-lowering drug, distinguishing it from traditional negative chronotropic agents such as beta-blockers and non-dihydropyridine calcium channel blockers.][3][ Its primary therapeutic effect is achieved by acting on the sinoatrial (SA) node, the heart's natural pacemaker, to reduce heart rate without deleteriously affecting myocardial contractility, intracardiac conduction, or ventricular repolarization.][5]

[The clinical utility of ivabradine is most firmly established in the management of chronic heart failure with reduced ejection fraction (HFrEF). The landmark Systolic Heart failure treatment with the If​ inhibitor ivabradine Trial (SHIFT) demonstrated that, when added to optimal guideline-directed medical therapy, ivabradine significantly reduces the risk of hospitalization for worsening heart failure in a specific subset of patients.][3][ Its role in chronic stable angina is more complex; while it provides symptomatic relief comparable to standard agents, its impact on hard cardiovascular outcomes has been a subject of considerable investigation, leading to different regulatory approvals globally.][1]

[This regulatory divergence is a key feature of ivabradine's clinical landscape. The U.S. Food and Drug Administration (FDA) has approved it primarily for the HFrEF indication validated by the SHIFT trial.][10][ In contrast, the European Medicines Agency (EMA) has authorized its use for both HFrEF and the symptomatic treatment of chronic stable angina, reflecting a different interpretation of the overall risk-benefit profile.][12]

[The safety profile of ivabradine is directly linked to its pharmacology. The most common adverse effects are bradycardia, a direct extension of its therapeutic action, and luminous visual phenomena (phosphenes), resulting from off-target inhibition of similar ion channels in the retina.][6][ A critical aspect of its risk management profile is its exclusive metabolism by the cytochrome P450 3A4 (CYP3A4) enzyme system. This metabolic pathway renders it highly susceptible to drug-drug interactions, necessitating stringent contraindications with potent CYP3A4 inhibitors and cautious use with moderate inhibitors and inducers.][3]

[In conclusion, ivabradine represents a targeted pharmacological intervention for cardiovascular diseases where elevated heart rate is a key pathophysiological driver and a modifiable risk factor. Its therapeutic niche is well-defined, serving as a valuable add-on or alternative therapy for specific, carefully selected patient populations.]

Chemical Profile and Physicochemical Properties

[A precise understanding of the chemical and physical characteristics of a therapeutic agent is fundamental to its study and clinical application. This section details the nomenclature, structural data, and physicochemical properties of ivabradine.]

2.1 Nomenclature and Standardized Identifiers

[To ensure unambiguous identification across scientific literature, clinical practice, and regulatory databases, ivabradine is cataloged under a comprehensive set of standardized names and identifiers.]

[The compound is most commonly known by its nonproprietary name, Ivabradine.][1][ Its systematic International Union of Pure and Applied Chemistry (IUPAC) name is 3-octa-1,3,5-trien-7-yl]methyl}(methyl)amino)propyl]-7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepin-2-one.][1][ The Chemical Abstracts Service (CAS) has assigned the number 155974-00-8 to the free base form of the molecule.][1][ The hydrochloride salt, which is the form used in many marketed drug products, is identified by CAS number 148849-67-6.][16]

[Ivabradine is extensively indexed in major chemical and pharmacological databases, which facilitates cross-referencing of data. A consolidated list of these identifiers is provided in Table 1.]

2.2 Molecular Structure and Formula

[Ivabradine is a complex small molecule belonging to the benzazepine class of compounds.][2][ Its chemical structure consists of a benzazepinone ring system linked to a benzocyclobutane moiety via an azapentane chain.][18]

• Molecular Formula:[ The empirical formula for the ivabradine free base is C27​H36​N2​O5​.][1]
• Stereochemistry:[ The structure contains a single asymmetric carbon atom, and the pharmacologically active form is the S-enantiomer.][18][ This stereospecificity is critical for its selective binding and inhibitory activity on its target ion channel.]
• Structural Identifiers:[ The molecule's two-dimensional and three-dimensional structure is unambiguously defined by standard chemical notations:]
• SMILES (Simplified Molecular-Input Line-Entry System):[ CN(CCCN1CCC2=CC(=C(C=C2CC1=O)OC)OC)C[C@H]3CC4=CC(=C(C=C34)OC)OC.][1]
• InChI (International Chemical Identifier):[ InChI=1S/C27H36N2O5/c1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30/h12-14,16,21H,6-11,15,17H2,1-5H3/t21-/m1/s1.][1]
• InChIKey:[ ACRHBAYQBXXRTO-OAQYLSRUSA-N.][1]

2.3 Physicochemical Characteristics

• Molar Mass:[ The average molecular weight of the free base is approximately 468.59 g·mol−1.][1][ The monoisotopic mass is approximately 468.2624 Da.][3][ The hydrochloride salt has a molecular weight of 505.05 g·mol−1.][17]
• Physical State and Solubility:[ The hydrochloride salt of ivabradine is a white, hygroscopic powder.][18][ It exhibits good solubility in water (50 mg/mL) and is also soluble in 0.9% saline solution (14 mg/mL) and DMSO.][16][ The pH of a 10 mg/mL aqueous solution ranges from 5.1 to 5.4.][18]
• Storage Conditions:[ For stability, ivabradine should be stored in a dry, dark environment. Recommended short-term storage is at 0-4°C, while long-term storage is at -20°C.][16]

2.4 Overview of Chemical Synthesis

[The synthesis of ivabradine is a multi-step process. A convergent synthesis has been described, which involves the coupling of two key intermediates: a benzocyclobutanyl amine derivative and an oxadioxalane fragment. This coupling is achieved through an in situ deprotection and reductive amination reaction, leading to the formation of the final ivabradine molecule, which is typically isolated as its hydrochloride salt.][2]

Table 1: Ivabradine Chemical and Drug Identifiers

Identifier Type	Value	Source(s)
Systematic (IUPAC) Name	3-octa-1,3,5-trien-7-yl]methyl}(methyl)amino)propyl]-7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepin-2-one	1
CAS Number (Free Base)	155974-00-8	1
CAS Number (HCl Salt)	148849-67-6	16
DrugBank ID	DB09083	1
PubChem CID	132999	1
ChEMBL ID	CHEMBL471737	1
ChEBI ID	CHEBI:85966	1
KEGG ID	D07165	1
UNII	3H48L0LPZQ	1
Molecular Formula	C27​H36​N2​O5​	1
SMILES	CN(CCCN1CCC2=CC(=C(C=C2CC1=O)OC)OC)C[C@H]3CC4=CC(=C(C=C34)OC)OC	1
InChIKey	ACRHBAYQBXXRTO-OAQYLSRUSA-N	1

Clinical Pharmacology

[The clinical utility of ivabradine is derived from its highly specific interaction with the electrical conduction system of the heart. Its pharmacological profile—encompassing its mechanism of action, pharmacodynamic effects, and pharmacokinetic properties—defines its therapeutic role and safety considerations.]

3.1 Mechanism of Action

[Ivabradine's mechanism is novel and distinct from other heart-rate-lowering agents. It is a selective and specific inhibitor of the cardiac pacemaker current, known as the "funny" current or If​.][1][ This current was so named because of its unusual properties compared to other ion currents known at the time of its discovery, such as its activation upon hyperpolarization of the cell membrane.][1]

• Molecular Target and Site of Action:[ The If​ current is conducted through Hyperpolarization-activated Cyclic Nucleotide-gated (HCN) channels.][5][ Ivabradine specifically targets the HCN4 isoform, which is highly expressed in the sinoatrial (SA) node, the heart's natural pacemaker.][1][ The drug binds to a specific site within the channel pore from the intracellular side.][3][ This action physically obstructs the flow of ions—a mixed inward current of sodium (] [Na+) and potassium (K+) ions—through the channel.][1]
• Physiological Consequence:[ The primary role of the If​ current is to control the rate of spontaneous diastolic depolarization in SA node pacemaker cells. This slow, spontaneous depolarization is what drives the SA node toward the threshold for firing an action potential, thereby setting the heart's rhythm. By inhibiting the If​ current, ivabradine reduces the slope of this diastolic depolarization phase. This effectively prolongs the time it takes for the pacemaker cells to reach the firing threshold, resulting in a selective and dose-dependent slowing of the heart rate (a negative chronotropic effect).][5]
• Pharmacological Specificity:[ A defining characteristic of ivabradine is its high degree of specificity. Unlike beta-blockers or calcium channel blockers, its mechanism is confined to the SA node's pacemaker activity. Extensive clinical electrophysiology studies have demonstrated that ivabradine has no significant effect on other critical aspects of cardiac function, including myocardial contractility (inotropy), the speed of cardiac relaxation (lusitropy), atrioventricular or intraventricular conduction times, or ventricular repolarization (as measured by the corrected QT interval).][3][ This profile as a "pure" heart-rate-lowering agent is fundamental to its therapeutic rationale. It allows for the reduction of heart rate—a key therapeutic goal in conditions like heart failure and angina—without the potentially undesirable side effects of reduced contractility or systemic blood pressure drops that can limit the use of other negative chronotropes.][4][ This targeted action explains its clinical niche as an add-on therapy for patients who are already on maximally tolerated doses of beta-blockers but still have an elevated heart rate, or as an alternative for those who cannot tolerate beta-blockers.]

3.2 Pharmacodynamics

[The pharmacodynamic effects of ivabradine are the direct clinical manifestations of its mechanism of action.]

• Heart Rate Reduction:[ Ivabradine induces a dose-dependent reduction in heart rate. This effect is more pronounced in individuals with higher baseline heart rates, meaning the drug is more effective when it is needed most.][6][ At the recommended therapeutic doses, ivabradine typically reduces the heart rate by approximately 10 beats per minute (bpm), both at rest and during exercise.][6]
• Use-Dependence and Plateau Effect:[ The drug exhibits a property known as "use-dependence," where its channel-blocking activity increases at faster heart rates.][3][ This is because ivabradine binds to the HCN channel when it is in the open state; at higher heart rates, the channels open and close more frequently, providing more opportunities for the drug to bind and exert its inhibitory effect.][5][ Conversely, the heart-rate-lowering effect tends to plateau at doses exceeding 20-40 mg twice daily.][3][ This plateau acts as an intrinsic safety feature, reducing the risk of profound or life-threatening bradycardia with accidental overdose.]
• Hemodynamic and Anti-Ischemic Effects:[ By slowing the heart rate, ivabradine decreases cardiac workload and, consequently, myocardial oxygen consumption.][18][ Simultaneously, the prolongation of the cardiac cycle primarily occurs during diastole. This is clinically significant because the majority of coronary artery blood flow to the myocardium occurs during diastole.][21][ By extending diastolic time, ivabradine improves coronary perfusion and increases myocardial oxygen supply. This dual effect of reducing oxygen demand while increasing oxygen supply is the basis for its anti-anginal and anti-ischemic properties.][1]
• Visual Phenomena (Phosphenes):[ A unique and characteristic pharmacodynamic effect of ivabradine is the potential for transient visual disturbances, which patients describe as phosphenes or sensations of enhanced brightness in a limited area of the visual field.][5][ This off-target effect is caused by ivabradine's partial inhibition of a closely related ion channel current,] [Ih​, found in the retina.][6][ The] [Ih​ current is involved in the temporal resolution of the visual system, particularly in adapting to rapid changes in light intensity.][18][ These visual symptoms are reported by approximately 14.5% of patients, are typically mild and transient, often appearing within the first two months of treatment, and are reversible upon discontinuation of the drug.][1]

3.3 Pharmacokinetics (ADME)

[The absorption, distribution, metabolism, and elimination (ADME) profile of ivabradine dictates its dosing regimen and is central to understanding its potential for drug-drug interactions.]

• Absorption:[ Following oral administration, ivabradine is rapidly and almost completely absorbed from the gastrointestinal tract. Under fasting conditions, it reaches peak plasma concentrations (Tmax​) in approximately one hour.][18][ However, its absolute oral bioavailability is relatively low, at around 40%, due to extensive first-pass metabolism in the gut wall and liver.][3][ The effect of food on absorption is clinically significant: taking ivabradine with meals delays absorption by about one hour but increases overall plasma exposure (AUC) by 20% to 40%.][3][ This increase in exposure helps to reduce intra-individual variability, and for this reason, it is consistently recommended that ivabradine be administered with food.][18]
• Distribution:[ Ivabradine is moderately bound to plasma proteins, at approximately 70%.][3][ It has a large apparent volume of distribution (] [Vd​) at steady state, close to 100 L, which indicates extensive distribution into tissues throughout the body.][3]
• Metabolism:[ The metabolism of ivabradine is a critical aspect of its clinical pharmacology. It is extensively metabolized, primarily in the liver and intestines, almost exclusively by the cytochrome P450 3A4 (CYP3A4) isoenzyme.][3][ This lack of redundant metabolic pathways makes ivabradine highly vulnerable to interactions with other drugs that inhibit or induce CYP3A4 activity. This vulnerability is the single most important pharmacokinetic factor driving its safety profile. Any substance that significantly alters CYP3A4 function can dramatically change ivabradine plasma concentrations, leading to either toxicity (from inhibitors) or loss of efficacy (from inducers). This directly informs the stringent contraindications and warnings associated with the drug. Ivabradine itself has a low affinity for CYP3A4 and is not expected to alter the metabolism of other CYP3A4 substrates.][3][ The major active metabolite of ivabradine is an N-desmethylated derivative (S 18982). This metabolite is pharmacologically equipotent to the parent compound, circulates at plasma concentrations approximately 40% that of ivabradine, and is also metabolized by CYP3A4, contributing to the overall therapeutic effect.][6]
• Elimination:[ Ivabradine is eliminated from the plasma with a main distribution half-life of approximately 2 hours and an effective elimination half-life of about 6 to 11 hours.][18][ The total body clearance is approximately 400 mL/min, with renal clearance accounting for only a small fraction of this (about 70 mL/min).][18][ Metabolites are excreted to a similar extent in both feces and urine. A very small amount, approximately 4%, of the orally administered dose is excreted unchanged in the urine.][3]

Table 2: Summary of Key Pharmacokinetic Parameters for Ivabradine

Parameter	Value / Description	Source(s)
Absolute Bioavailability	~40% (due to extensive first-pass metabolism)	3
Time to Peak Plasma Conc. (Tmax​)	~1 hour (fasting); delayed by ~1 hour with food	21
Food Effect	Increases plasma exposure (AUC) by 20-40%; recommended to be taken with food to reduce variability	3
Plasma Protein Binding	~70%	3
Volume of Distribution (Vd​)	~100 L	3
Metabolism	Extensive, via intestinal and hepatic Cytochrome P450 3A4 (CYP3A4) only	3
Active Metabolite	N-desmethylated derivative (S 18982), equipotent to parent drug	6
Elimination Half-life	Main: ~2 hours; Effective: ~6-11 hours	21
Total Clearance	~400 mL/min	22
Route of Excretion	Metabolites excreted equally in feces and urine; ~4% of dose excreted unchanged in urine	3

Clinical Efficacy and Evidence from Major Trials

[The clinical role of ivabradine has been defined by a series of large-scale, randomized controlled trials. The evidence from these studies, particularly SHIFT, BEAUTIFUL, and SIGNIFY, has shaped its approved indications and provides critical context for its use in different cardiovascular conditions.]

4.1 Heart Failure with Reduced Ejection Fraction (HFrEF)

[The strongest evidence for ivabradine's benefit comes from its use in patients with symptomatic HFrEF. Elevated heart rate in this population is not just a symptom but a recognized modifiable risk factor for adverse outcomes.][27]

• The SHIFT Trial (Systolic Heart failure treatment with the If​ inhibitor ivabradine Trial):[ This was the pivotal, cornerstone trial that established the role of ivabradine in HFrEF.][28]
• Trial Design and Population:[ SHIFT was a large, multinational, randomized, double-blind, placebo-controlled study that enrolled 6,558 patients.][8][ The inclusion criteria were highly specific, targeting a population with stable, symptomatic (New York Heart Association class II-IV) chronic HFrEF, a left ventricular ejection fraction (LVEF) of 35% or less, a normal sinus rhythm, and a resting heart rate of 70 bpm or higher.][7][ Crucially, patients were required to be on stable, optimal background medical therapy, and 89% of participants were receiving a beta-blocker at baseline.][29]
• Primary Endpoint:[ The primary composite endpoint was the first occurrence of either cardiovascular (CV) death or hospitalization for worsening heart failure.][8]
• Key Outcomes:[ Over a median follow-up of 22.9 months, ivabradine demonstrated a statistically significant and clinically meaningful benefit. It reduced the primary endpoint by 18% compared to placebo (hazard ratio 0.82, 95% CI 0.75-0.90; p<0.0001).][8][ This positive result was primarily driven by a substantial 26% reduction in the risk of hospitalization for worsening heart failure (HR 0.74; p<0.0001).][29][ The trial also showed a significant reduction in deaths specifically due to heart failure.][31][ However, there was no statistically significant reduction in all-cause mortality or overall CV mortality.][29][ The benefit of ivabradine was observed to be even more pronounced in patients with higher baseline heart rates (e.g., ≥77 bpm).][29]
• Clinical Role and Therapeutic Context:[ The results of the SHIFT trial were practice-changing. They validated heart rate as an independent therapeutic target in HFrEF. The fact that ivabradine conferred benefit on top of existing optimal therapy, including high rates of beta-blocker use, was particularly important. It demonstrated that even in patients treated with beta-blockers, residual tachycardia (HR ≥70 bpm) remains a significant risk factor that can be addressed with a complementary mechanism. Ivabradine's ability to further lower heart rate without causing the hypotension or fatigue that often limits beta-blocker up-titration established its role.][23][ Consequently, clinical guidelines now recommend ivabradine as an add-on therapy for the specific HFrEF patient profile studied in SHIFT: those who remain symptomatic with an LVEF ≤35% and a resting heart rate ≥70 bpm in sinus rhythm, despite being on a maximally tolerated dose of a beta-blocker (or having a contraindication to beta-blocker use).][3][ It is emphasized that ivabradine is not a substitute for beta-blockers, which have a proven mortality benefit.][33]

4.2 Chronic Stable Angina

[The evidence base for ivabradine in chronic stable angina is more nuanced and has evolved over time. While its mechanism of reducing myocardial oxygen demand and improving supply provides a strong rationale for its use, its impact on hard outcomes has been less consistent than in HFrEF.]

• Early Efficacy and Combination Therapy Trials:[ Initial studies successfully established ivabradine's anti-anginal efficacy. Non-inferiority trials demonstrated that, as monotherapy, it was as effective as the beta-blocker atenolol and the calcium channel blocker amlodipine in improving total exercise duration and reducing angina symptoms.][1][ The ASSOCIATE trial further showed that adding ivabradine to a background of atenolol provided additional efficacy, supporting its use in combination therapy.][34]
• The BEAUTIFUL Trial (Morbidity-mortality EvAlUation of the If​ inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction):[ This large trial enrolled 10,917 patients with stable coronary artery disease (CAD) and LV dysfunction (LVEF <40%).][5]
• Overall Outcome:[ In the total study population, the trial was neutral. Ivabradine did not significantly reduce the primary composite endpoint of CV death, hospitalization for myocardial infarction (MI), or hospitalization for new or worsening heart failure.][5]
• Key Subgroup Analysis:[ A pre-specified subgroup analysis of patients with a baseline heart rate of 70 bpm or higher yielded important findings. In this tachycardic subgroup, ivabradine significantly reduced the risk of admission for fatal and non-fatal MI and the need for coronary revascularization.][5][ This suggested that, similar to HFrEF, the benefit in CAD might be concentrated in patients with elevated heart rates.]
• The SIGNIFY Trial (Study assessInG the morbidity-mortality beNefits of the If​ inhibitor ivabradine in patients with coronarY artery disease):[ This very large trial (n=19,102) was designed to definitively test the hypothesis that heart rate reduction with ivabradine improves outcomes in patients with stable CAD ]without[ clinical heart failure.][9]
• Outcome:[ The results of SIGNIFY were pivotal and ultimately negative. The study not only failed to show a benefit but revealed a small yet statistically significant ]increase[ in the risk of the primary composite endpoint (CV death or non-fatal MI) in a subgroup of patients with activity-limiting angina (NYHA class ≥II).][9][ This unexpected finding prompted a safety review by the EMA and led to a more cautious approach to the use of ivabradine in the broad population of patients with stable angina without heart failure.]
• Synthesis of Angina Evidence:[ The journey of ivabradine in angina illustrates the critical importance of patient selection and the danger of extrapolating findings from one disease state to another. While effective for symptom control, its impact on major adverse cardiac events is highly dependent on the patient's clinical profile. The success in the HFrEF population of the SHIFT trial could not be replicated in the broader stable CAD population of the SIGNIFY trial. The data collectively suggest that any potential benefit on hard outcomes in CAD is likely restricted to a narrow subgroup of patients, such as those with concomitant LV dysfunction and a high resting heart rate, as hinted at by the BEAUTIFUL trial. This complex evidence base is directly responsible for the divergent regulatory approvals for the angina indication between the US and Europe.]

4.3 Investigational and Off-Label Applications

[Given its specific mechanism of slowing the heart's natural pacemaker, ivabradine has been explored for other conditions characterized by sinus tachycardia.]

• Inappropriate Sinus Tachycardia (IST):[ Due to its direct action on the SA node, ivabradine is a logical choice for treating IST, a condition defined by a persistent, non-paroxysmal sinus tachycardia without a clear physiological cause. It is frequently and effectively used off-label for this purpose.][1][ Some health insurance plans may even provide coverage for this use, despite it not being an FDA-approved indication.][38]
• Postural Orthostatic Tachycardia Syndrome (POTS):[ Many cardiologists have found success using ivabradine to manage the exaggerated heart rate response that defines POTS.][1][ Its use has been documented experimentally, including in patients experiencing POTS as a sequela of long COVID.][1]
• Other Investigational Uses:[ Clinical trials are actively recruiting patients to investigate the potential role of ivabradine, often in combination with beta-blockers like carvedilol, in the management of portal hypertension.][39]

Table 3: Comparative Summary of Pivotal Ivabradine Clinical Trials

Feature	SHIFT	BEAUTIFUL	SIGNIFY
Primary Condition	Chronic Heart Failure with Reduced EF (HFrEF)	Stable Coronary Artery Disease (CAD) with LV Dysfunction	Stable CAD without Heart Failure
Patient Population	6,558 patients; LVEF ≤35%; HR ≥70 bpm; Symptomatic (NYHA II-IV)	10,917 patients; LVEF <40%	19,102 patients; No clinical HF
Primary Endpoint	Composite of CV death or hospitalization for worsening HF	Composite of CV death, hospitalization for MI, or hospitalization for worsening HF	Composite of CV death or non-fatal MI
Key Findings	Positive: 18% reduction in primary endpoint (HR 0.82), driven by reduced HF hospitalizations. Established efficacy in HFrEF.	Neutral (Overall): No significant difference in primary endpoint. Subgroup Benefit: In patients with HR ≥70 bpm, reduced MI and revascularization.	Negative: No benefit in overall population. Potential Harm: Small but significant increase in primary endpoint risk in patients with limiting angina.
Clinical Implication	Practice-changing; established ivabradine as add-on therapy for a specific HFrEF population.	Provided nuanced evidence suggesting benefit may be limited to tachycardic CAD patients with LV dysfunction.	Served as a cautionary tale against broad use in stable CAD; led to more restrictive prescribing guidelines.
Source(s)	8	5	9

Regulatory Status and Prescribing Information

[The global clinical use of ivabradine is governed by the approvals and guidelines set forth by national and regional regulatory bodies. A notable feature of ivabradine is the significant divergence in its approved indications between the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This divergence is a direct reflection of how the same body of clinical trial evidence, particularly the contrasting results of the SHIFT and SIGNIFY trials, can be interpreted differently in terms of risk-benefit assessment.]

5.1 U.S. Food and Drug Administration (FDA)

[In the United States, ivabradine is marketed under the brand name Corlanor®. Its approval is narrow and focuses almost exclusively on the heart failure indication where the evidence for benefit is most robust.]

• Approved Indications:
• Adult Patients:[ Ivabradine is indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic HFrEF. The specific criteria for this indication are an LVEF of 35% or less, being in normal sinus rhythm with a resting heart rate of 70 bpm or higher, and being on maximally tolerated doses of beta-blockers or having a contraindication to beta-blocker use.][3]
• Pediatric Patients:[ It is also indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged 6 months and older who are in sinus rhythm and have an elevated heart rate.][10]
• Dosage and Administration (Adults):[ The recommended starting dose is 5 mg twice daily, taken with food. After two weeks, the dose is adjusted based on the patient's resting heart rate, with a target range of 50 to 60 bpm. The dose can be increased to a maximum of 7.5 mg twice daily. A lower starting dose of 2.5 mg twice daily is recommended for patients with a history of conduction defects or in whom bradycardia could lead to hemodynamic compromise.][10]

5.2 European Medicines Agency (EMA)

[In the European Union, ivabradine is marketed under brand names such as Procoralan®, Corlentor®, and various generic versions. The EMA has approved a broader set of indications, including a role in the management of chronic stable angina.]

• Approved Indications:
• Chronic Stable Angina:[ Ivabradine is indicated for the symptomatic treatment of chronic stable angina in adults with normal sinus rhythm and a heart rate of 70 bpm or higher. It can be used as an alternative therapy for patients who cannot tolerate or have a contraindication to beta-blockers, or as a combination therapy in patients who are inadequately controlled with an optimal beta-blocker dose.][12]
• Chronic Heart Failure:[ The indication is for the treatment of chronic heart failure (NYHA class II-IV) in patients with systolic dysfunction who are in sinus rhythm and have a resting heart rate of 75 bpm or higher. It is used in combination with standard therapy, including a beta-blocker, or when beta-blocker therapy is contraindicated or not tolerated.][12]
• Dosage and Administration:[ The starting dose is typically 5 mg twice daily. For elderly patients (over 75 years), a lower starting dose of 2.5 mg twice daily may be considered. A key stipulation for the angina indication is that treatment should be discontinued if there is no improvement in symptoms after three months.][12]

[The differing regulatory stances highlight that drug approval is not merely a reflection of raw data but involves a complex judgment of the risk-benefit equation for a given population. The FDA's more conservative approach, withholding an angina indication, likely places greater weight on the potential for harm suggested by the SIGNIFY trial in a broad CAD population. The EMA's label, in contrast, reflects a view that for specific, well-defined angina patient subgroups (e.g., those intolerant to first-line agents), the established symptomatic benefit may outweigh the risks. Even the heart rate thresholds for the heart failure indication differ slightly (FDA: ≥70 bpm; EMA: ≥75 bpm), underscoring subtle differences in the statistical interpretation of the SHIFT trial data. This regulatory divergence is a clear illustration that the path from clinical evidence to clinical practice can vary depending on regional risk tolerance and the perceived therapeutic need.]

Table 4: Comparison of FDA and EMA Approved Indications and Key Prescribing Criteria for Ivabradine

Feature	U.S. Food and Drug Administration (FDA)	European Medicines Agency (EMA)
Primary Indication 1	Heart Failure (HFrEF): To reduce hospitalization for worsening HF in stable, symptomatic adults.	Heart Failure: Treatment of chronic HF (NYHA II-IV) in adults with systolic dysfunction.
Key HFrEF Criteria	LVEF ≤35%; Resting HR ≥70 bpm; Sinus Rhythm; On max-tolerated beta-blocker or has contraindication.	Resting HR ≥75 bpm; Sinus Rhythm; In combination with standard therapy or when beta-blockers are contraindicated/not tolerated.
Primary Indication 2	Pediatric Heart Failure: Stable symptomatic HF due to dilated cardiomyopathy (DCM) in patients ≥6 months old.	Chronic Stable Angina: Symptomatic treatment in adults.
Key Angina Criteria	Not Approved	Normal Sinus Rhythm; Resting HR ≥70 bpm; Used as alternative to or in combination with beta-blockers.
Unique Dosing Notes	Start 2.5 mg BID in patients with conduction defects.	Start 2.5 mg BID in patients >75 years. Stop treatment for angina if no benefit after 3 months.
Source(s)	10	12

Safety, Tolerability, and Risk Management

[The safety profile of ivabradine is well-characterized and is intrinsically linked to its specific pharmacology. Effective risk management requires a thorough understanding of its potential adverse effects, clinically significant drug-drug interactions, and contraindications.]

6.1 Adverse Drug Reactions (ADRs)

[The most frequently reported adverse reactions are direct consequences of ivabradine's effects on ion channels in the heart and the retina.]

• Bradycardia:[ As a direct extension of its therapeutic mechanism, an excessive slowing of the heart rate is the most common hemodynamically significant adverse effect. In the SHIFT trial, symptomatic bradycardia was reported in 5% of patients treated with ivabradine, compared to 1% in the placebo group.][29][ Asymptomatic bradycardia is also common.][11][ This underscores the critical need for regular heart rate monitoring during treatment initiation and dose titration.][6]
• Luminous Phenomena (Phosphenes):[ This is the most common side effect overall, reported to affect more than 1 in 10 patients (up to 14.5%).][1][ These are described as transient episodes of enhanced brightness in the visual field, often triggered by sudden changes in light intensity.][14][ The effect is due to the inhibition of retinal] [Ih​ channels. While generally considered mild and transient, and reversible upon drug discontinuation, patients should be counseled about this potential effect, particularly if their occupations involve driving or operating machinery.][5]
• Atrial Fibrillation (AF):[ Clinical trials have consistently shown that ivabradine is associated with a small but statistically significant increased risk of developing new-onset atrial fibrillation.][5][ The SIGNIFY trial reported a 1.5% absolute risk increase over a 28-month period.][24][ Therefore, patients should be monitored regularly for the development of AF, as this would typically necessitate discontinuation of ivabradine.][11]
• Other Reported ADRs:[ Hypertension has also been reported as a common adverse reaction in clinical trials.][40]

6.2 Drug-Drug Interactions

[Ivabradine's complete dependence on the CYP3A4 enzyme for its metabolism makes it highly susceptible to drug-drug interactions. This is the most critical area for risk management when prescribing the drug.]

• CYP3A4-Based Interactions:
• Strong CYP3A4 Inhibitors:[ Co-administration of ivabradine with potent inhibitors of CYP3A4 is ]contraindicated[. These agents (e.g., azole antifungals like itraconazole and ketoconazole, macrolide antibiotics like clarithromycin and telithromycin, HIV protease inhibitors like ritonavir and nelfinavir, and nefazodone) can dramatically increase plasma concentrations of ivabradine, leading to a profound risk of excessive bradycardia and conduction disturbances.][3]
• Moderate CYP3A4 Inhibitors:[ Co-administration with moderate inhibitors (e.g., the non-dihydropyridine calcium channel blockers diltiazem and verapamil, and grapefruit juice) should be avoided or undertaken only with extreme caution, dose reduction, and close monitoring. These agents can still cause clinically significant increases in ivabradine exposure.][6]
• CYP3A4 Inducers:[ Conversely, co-administration with potent inducers of CYP3A4 (e.g., St. John's wort, rifampicin, barbiturates, phenytoin) can significantly decrease ivabradine plasma concentrations, leading to a loss of efficacy. The concomitant use of these agents should be avoided or may necessitate an increase in the ivabradine dose with careful monitoring of its effect.][6]
• Pharmacodynamic Interactions:
• Other Negative Chronotropes:[ The bradycardic effect of ivabradine is additive with that of other heart-rate-slowing drugs. Concomitant use with agents such as beta-blockers, digoxin, and amiodarone increases the risk of excessive bradycardia. While combination with beta-blockers is an approved indication, careful monitoring of heart rate is essential.][6]

6.3 Contraindications, Warnings, and Special Populations

[The use of ivabradine is restricted in several clinical scenarios to prevent adverse outcomes.]

• Absolute Contraindications:[ A consolidated list from the FDA and EMA labels includes:]
• [Acute decompensated heart failure.][10]
• [Clinically significant hypotension (e.g., blood pressure < 90/50 mmHg).][10]
• [Sick sinus syndrome, sinoatrial block, or 3rd-degree atrioventricular (AV) block, unless a functioning demand pacemaker is present.][10]
• [Severe hepatic impairment.][10]
• [Pacemaker dependence (where the heart rate is maintained exclusively by a pacemaker).][10]
• [Resting heart rate below a specified threshold prior to treatment (FDA: <60 bpm; EMA: <70 bpm).][11]
• [Concomitant use of strong CYP3A4 inhibitors.][10]
• Warnings and Precautions:
• Fetal Toxicity:[ Ivabradine has demonstrated embryo-fetal toxicity and cardiac teratogenic effects in animal studies. It may cause fetal harm when administered to a pregnant woman. Therefore, females of reproductive potential must be advised to use effective contraception during treatment.][3]
• Lactation:[ Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended during treatment with ivabradine.][7]
• Use in Specific Populations:
• Hepatic Impairment:[ While contraindicated in severe hepatic impairment, no dose adjustment is required for patients with mild or moderate impairment.][7]
• Renal Impairment:[ No dose adjustment is needed for patients with a creatinine clearance (CrCl) between 15 and 60 mL/min. Data are not available for patients with severe renal impairment (CrCl < 15 mL/min), and it should be used with caution in this group.][7]

Table 5: Clinically Significant Drug-Drug Interactions with Ivabradine and Management Strategies

Interacting Agent Class	Examples	Clinical Effect on Ivabradine	Management Recommendation	Source(s)
Strong CYP3A4 Inhibitors	Itraconazole, Ketoconazole, Clarithromycin, Ritonavir, Nelfinavir	Dramatically increases plasma concentration and risk of severe bradycardia	Contraindicated	6
Moderate CYP3A4 Inhibitors	Diltiazem, Verapamil, Grapefruit Juice	Significantly increases plasma concentration and risk of bradycardia	Avoid concomitant use. If necessary, use with caution, consider a lower starting dose, and monitor heart rate closely.	6
Strong CYP3A4 Inducers	Rifampicin, St. John's Wort, Phenytoin, Barbiturates	Significantly decreases plasma concentration, leading to loss of efficacy	Avoid concomitant use. If necessary, a higher dose of ivabradine may be required with close monitoring.	6
Other Negative Chronotropes	Beta-blockers, Digoxin, Amiodarone	Additive pharmacodynamic effect, increasing the risk of bradycardia	Use with caution and monitor heart rate closely. Combination with beta-blockers is an approved indication.	6
QTc-Prolonging Drugs	Ajmaline, certain antipsychotics	May increase the risk of QTc prolongation, although ivabradine itself does not prolong the QTc interval	Monitor ECG and use with caution.	3

Conclusion and Expert Synthesis

[Ivabradine has carved out a distinct and important niche in the armamentarium of cardiovascular therapeutics. Its identity as a "pure" chronotropic agent, derived from its selective inhibition of the If​ current in the sinoatrial node, represents a triumph of targeted drug design. This specificity allows it to lower heart rate—a key therapeutic goal in both heart failure and angina—without the confounding negative inotropic or vasodilatory effects that characterize broader-acting agents like beta-blockers.]

[The clinical evidence base for ivabradine tells a compelling, albeit complex, story. The SHIFT trial provided unequivocal evidence of its benefit in a well-defined population of patients with heart failure with reduced ejection fraction, validating not only the drug itself but also the concept of residual tachycardia as a modifiable risk factor. In this context, ivabradine serves as a crucial complementary therapy, achieving further heart rate reduction and reducing hospitalizations in patients who remain tachycardic despite optimal neurohormonal blockade.]

[In contrast, the journey of ivabradine in chronic stable angina serves as a powerful lesson in the importance of patient selection and the perils of extrapolating a drug's benefit based on its mechanism alone. The negative outcome of the SIGNIFY trial, which studied a broad population of stable CAD patients without heart failure, demonstrated that the benefits seen in HFrEF are not universally applicable. The underlying pathophysiology of the disease state is paramount; the neurohormonal milieu of heart failure creates a context where pure heart rate reduction is beneficial, whereas in stable CAD without heart failure, the risk-benefit calculus is far less favorable and potentially negative. This nuanced evidence base is rightly reflected in the divergent regulatory approvals between the FDA and EMA.]

[From a practical standpoint, the safe use of ivabradine hinges on two principles: meticulous patient selection according to evidence-based criteria and vigilant management of its pharmacokinetic vulnerabilities. Its exclusive metabolism by CYP3A4 necessitates a thorough review of concomitant medications to avoid potentially hazardous drug-drug interactions.]

[Looking forward, the logical application of ivabradine's targeted mechanism continues to be explored in other tachyarrhythmias, such as inappropriate sinus tachycardia and postural orthostatic tachycardia syndrome, where it holds significant promise. Ultimately, the story of ivabradine is a masterclass in modern cardiovascular pharmacology, highlighting the power of a specific mechanism, the critical importance of defining the right patient population through rigorous clinical trials, and the ongoing need to refine therapeutic strategies to match the drug to the disease.]

Works cited

1. Ivabradine - Wikipedia, accessed July 21, 2025, https://en.wikipedia.org/wiki/Ivabradine
2. Ivabradine | 155974-00-8 - ChemicalBook, accessed July 21, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB41178988.htm
3. Ivabradine: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 21, 2025, https://go.drugbank.com/drugs/DB09083
4. What is the mechanism of Ivabradine Hydrochloride? - Patsnap Synapse, accessed July 21, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-ivabradine-hydrochloride
5. The Clinical Use of Ivabradine | JACC, accessed July 21, 2025, https://www.jacc.org/doi/10.1016/j.jacc.2017.08.038
6. Ivabradine (Corlanor) for Heart Failure: The First Selective and Specific If Inhibitor - PMC, accessed July 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4671466/
7. Corlanor (Ivabradine), First HCN Channel Blocker, FDA Approved for the Treatment of Patients with Heart Failure - PMC, accessed July 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5013853/
8. What are the BEAUTIFUL (MorBidity-mortality EvAlUation of the IF inhibitor ivabradine in patients with coronary disease and left ventriculAr dysfunction) and SHIFT (Systolic Heart failure treatment with the IF inhibitor ivabradine Trial) trials for ivabradine (ivabradine)? - Dr.Oracle AI, accessed July 21, 2025, https://www.droracle.ai/articles/92530/what-are-the-beautiful-and-shift-trials-for-ivabradine
9. Amgen Statement on EMA Review of Ivabradine, accessed July 21, 2025, https://www.amgen.com/newsroom/company-statements/archives/statements-and-responses/amgen-statement-on-ema-review-of-ivabradine
10. CORLANOR® (ivabradine) Label - accessdata.fda.gov, accessed July 21, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209964lbl.pdf
11. Reference ID: 3732763 This label may not be the latest approved by FDA. For current labeling information, please visit https:// - accessdata.fda.gov, accessed July 21, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206143orig1s000lbl.pdf
12. Ivabradine Anpharm | European Medicines Agency (EMA), accessed July 21, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/ivabradine-anpharm
13. Ivabradine Accord | European Medicines Agency (EMA), accessed July 21, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/ivabradine-accord
14. Ivabradine: Package Insert / Prescribing Information - Drugs.com, accessed July 21, 2025, https://www.drugs.com/pro/ivabradine.html
15. Ivabradine | C27H36N2O5 | CID 132999 - PubChem, accessed July 21, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Ivabradine
16. Ivabradine | CAS# 155974-00-8 | bradycardic agent - MedKoo Biosciences, accessed July 21, 2025, https://www.medkoo.com/products/44131
17. Ivabradine Hydrochloride - LGC Standards, accessed July 21, 2025, https://www.lgcstandards.com/PS/en/Ivabradine-Hydrochloride/p/TRC-I940500
18. Product information for Coralan - Therapeutic Goods Administration (TGA), accessed July 21, 2025, https://www.tga.gov.au/sites/default/files/auspar-ivabradine-121031-pi.pdf
19. Ivabradine | CAS 155974-00-8 | SCBT - Santa Cruz Biotechnology, accessed July 21, 2025, https://www.scbt.com/p/ivabradine-155974-00-8
20. Ivabradine | CAS 155974-00-8 | AbMole BioScience, accessed July 21, 2025, https://www.abmole.com/products/ivabradine.html
21. Role of ivabradine in management of stable angina in patients with different clinical profiles, accessed July 21, 2025, https://openheart.bmj.com/content/5/1/e000725
22. Ivabradine - StatPearls - NCBI Bookshelf, accessed July 21, 2025, https://www.ncbi.nlm.nih.gov/books/NBK507783/
23. Ivabradine vs Beta Blockers in Heart Failure: Understanding the Differences - Knya, accessed July 21, 2025, https://knyamed.com/blogs/difference-between/ivabradine-vs-beta-blockers-for-heart-failure
24. Ivabradine | Circulation - American Heart Association Journals, accessed July 21, 2025, https://www.ahajournals.org/doi/10.1161/circulationaha.115.018094
25. FDA News Issue 14, May 2019 - ASCPT, accessed July 21, 2025, [https://www.ascpt.org/Resources/ASCPT-News/View/articleid/23889?dnnprintmode=true&mid=16095&SkinSrc=[G]Skins%2F_default%2FNo+Skin&ContainerSrc=[G]Containers%2F_default%2FNo+Container](https://www.google.com/url?q=https://www.ascpt.org/Resources/ASCPT-News/View/articleid/23889?dnnprintmode%3Dtrue%26mid%3D16095%26SkinSrc%3D%255BG%255DSkins/_default/No%2BSkin%26ContainerSrc%3D%255BG%255DContainers/_default/No%2BContainer&sa=D&source=editors&ust=1753091622820613&usg=AOvVaw3qdrOxw012G37dU01Yk2QD)
26. Procoralan, INN-ivabradine - EMA, accessed July 21, 2025, https://www.ema.europa.eu/en/documents/product-information/procoralan-epar-product-information_en.pdf
27. Effects on Outcomes of Heart Rate Reduction by Ivabradine in Patients With Congestive Heart Failure: Is There an Influence of Beta-Blocker Dose?: Findings From the SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) Study | JACC, accessed July 21, 2025, https://www.jacc.org/doi/10.1016/j.jacc.2012.01.020
28. Ivabradine in Heart Failure, accessed July 21, 2025, https://www.ahajournals.org/doi/pdf/10.1161/circheartfailure.117.004112
29. Systolic Heart failure treatment with the IF inhibitor ivabradine Trial ..., accessed July 21, 2025, https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2012/05/20/16/30/SHIFT
30. Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study (SHIFT) - ClinicalTrials.gov, accessed July 21, 2025, https://clinicaltrials.gov/study/NCT02441218
31. The EMA approves ivabradine for the treatment of chronic heart failure, accessed July 21, 2025, https://www.iscpcardio.org/expert-opinions/treatment-chronic-heart-failure/
32. Complementary and Synergic Role of Combined Beta-blockers and Ivabradine in Patients with Chronic Heart Failure and Depressed Systolic Function: A New Therapeutic Option?, accessed July 21, 2025, https://www.cfrjournal.com/articles/complementary-and-synergic-role-combined-beta-blockers-and-ivabradine-patients-chronic?language_content_entity=en
33. Promising New Therapies in Heart Failure: Ivabradine and the ..., accessed July 21, 2025, https://www.uscjournal.com/articles/promising-new-therapies-heart-failure-ivabradine-and-neprilysin-inhibitors?language_content_entity=en
34. New EU Drug Indication Allows Combination With Beta Blockers for Angina | DAIC, accessed July 21, 2025, https://www.dicardiology.com/content/new-eu-drug-indication-allows-combination-beta-blockers-angina
35. What are the BEAUTIFUL (MorBidity-mortality EvAlUation of the IF inhibitor ivabradine in patients with coronary disease and left ventriculAr dysfunction) and SHIFT (Systolic Heart failure treatment with the IF inhibitor ivabradine Trial) trials for ivabradine (ivabradine)? - Dr.Oracle AI Medical Assistant, accessed July 21, 2025, https://www.droracle.ai/articles/92531/what-are-the-beautiful-and-shift-trials-for-ivabradine
36. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials - Oxford Academic, accessed July 21, 2025, https://academic.oup.com/eurheartj/article/34/29/2263/401143
37. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial - PubMed, accessed July 21, 2025, https://pubmed.ncbi.nlm.nih.gov/19720635/
38. Corlanor® (ivabradine) - Prior Authorization/Medical Necessity - UnitedHealthcare Commercial Plans - UHCprovider.com, accessed July 21, 2025, https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/a-g/PA-Med-Nec-Corlanor.pdf
39. Portal Hypertension Recruiting Phase Trials for Ivabradine (DB09083) | DrugBank Online, accessed July 21, 2025, https://go.drugbank.com/indications/DBCOND0029015/clinical_trials/DB09083?status=recruiting
40. FDA Approves New Heart Failure Drug - American College of Cardiology, accessed July 21, 2025, https://www.acc.org/Latest-in-Cardiology/Articles/2015/04/16/13/14/FDA-Approves-New-Heart-Failure-Drug